Announcement

Collapse
No announcement yet.

Cardiovasc Drugs Ther . A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Cardiovasc Drugs Ther . A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs


    Cardiovasc Drugs Ther


    . 2020 Jun 17.
    doi: 10.1007/s10557-020-07024-7. Online ahead of print.
    A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs


    Wen-Liang Yu 1 2 , Han Siong Toh 1 3 , Chia-Te Liao 4 5 , Wei-Ting Chang 6 7 8



    Affiliations

    Abstract

    Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Several candidate drugs have been screened and are currently under investigation. These primarily include antiviral regimens and immunomodulatory regimens. However, beyond the anti-SARS-CoV-2 effects, these drugs may also have risks to the cardiovascular system, especially altering cardiac conduction. Herein, we review the cardiovascular risks of potential anti-COVID-19 drugs.

    Keywords: COVID-19; Complications; Potential cardiotoxicity; SARS-CoV-2.

Working...
X